Evaluar la seguridad y efectividad de la Hidroxicloroquina y Remdesivir como tratamiento farmacológico para SARS- CoV-2
Fecha
2021
Autores
Título de la revista
ISSN de la revista
Título del volumen
Editor
Universidad de Guayaquil. Facultad de Ciencias Químicas
Resumen
La pandemia Covid-19 causada por el SARS-CoV-2 constituye el mayor problema de salud pública en la última centena de años, al nivel de emergencia sanitaria mundial. Afecta a pacientes de todas las edades, particularmente a personas con riesgos de enfermedades cardiovasculares, hipertensión, diabetes tipo 2, problemas renales y obesidades. El presente trabajo tiene como objetivo evaluar la seguridad y efectividad de la Hidroxicloroquina y Remdesivir como tratamiento farmacológico para SARS-CoV-2. La investigación se desarrolló con un enfoque mixto, cualitativo y cuantitativo, con recolección de datos bibliográficos, de tipo descriptivo no experimental y transversal. Estos fármacos tuvieron aprobación de uso por emergencia de la FDA, al inicio de la pandemia COVID-19, debido al acontecimiento sanitario, social y económico similar a la de una guerra en todo el mundo; considerando que la reutilización de medicamentos reduce los tiempos de descubrimiento y desarrollo, disminuyendo los costos generales, así como la mayoría de las pruebas preclínicas y clínicas, incluidos los perfiles de seguridad y farmacocinéticos. En referencia a la revisión de las 20 publicaciones estudiadas, se concluyó que el Remdesivir es más eficiente y seguro que la Hidroxicloroquina, sobre todo en la primera etapa del tratamiento a nivel de hospitalización, reduciendo del tiempo de recuperación y tasa de mortalidad menor a 10 días, lo que puede indicar un efecto beneficioso, pero estadísticamente no significativo. Teniendo en cuenta, que el estudio no tenía suficiente poder estadístico para evaluar la mortalidad; esta sigue siendo de carácter investigativo.
The Covid-19 pandemic caused by SARS-CoV-2 constitutes the greatest public health problem in the last hundred years, at the level of a global health emergency. It affects patients of all ages, particularly people at risk for cardiovascular disease, hypertension, type 2 diabetes, kidney problems, and obesity. The present work aims to evaluate the safety and effectiveness of Hydroxychloroquine and Remdesivir as pharmacological treatment for SARS-CoV-2. The research was developed with a mixed, qualitative and quantitative approach, with collection of bibliographic data, descriptive, non-experimental and cross-sectional. These drugs were approved for emergency use by the FDA, at the beginning of the COVID-19 pandemic, due to the health, social and economic event similar to that of a war around the world; considering that drug reuse reduces discovery and development times, lowering overall costs, as well as most preclinical and clinical testing, including safety and pharmacokinetic profiles. In reference to the review of the 20 publications studied, it was concluded that Remdesivir is more efficient and safer than Hydroxychloroquine, especially in the first stage of treatment at the hospitalization level, reducing the recovery time and mortality rate of less than 10 days, which may indicate a beneficial effect, but not statistically significant. Taking into account that the study did not have sufficient statistical power to evaluate mortality; this is still investigative in nature.
The Covid-19 pandemic caused by SARS-CoV-2 constitutes the greatest public health problem in the last hundred years, at the level of a global health emergency. It affects patients of all ages, particularly people at risk for cardiovascular disease, hypertension, type 2 diabetes, kidney problems, and obesity. The present work aims to evaluate the safety and effectiveness of Hydroxychloroquine and Remdesivir as pharmacological treatment for SARS-CoV-2. The research was developed with a mixed, qualitative and quantitative approach, with collection of bibliographic data, descriptive, non-experimental and cross-sectional. These drugs were approved for emergency use by the FDA, at the beginning of the COVID-19 pandemic, due to the health, social and economic event similar to that of a war around the world; considering that drug reuse reduces discovery and development times, lowering overall costs, as well as most preclinical and clinical testing, including safety and pharmacokinetic profiles. In reference to the review of the 20 publications studied, it was concluded that Remdesivir is more efficient and safer than Hydroxychloroquine, especially in the first stage of treatment at the hospitalization level, reducing the recovery time and mortality rate of less than 10 days, which may indicate a beneficial effect, but not statistically significant. Taking into account that the study did not have sufficient statistical power to evaluate mortality; this is still investigative in nature.
Descripción
Pdf
Palabras clave
CORONAVIRUS, EVENTOS ADVERSOS, COMORBILIDAD